{"podcast":{"title":"Toronto News Today | 2 Min News | The Daily News Now!","slug":"toronto-news-today-2-min-news-the-daily-news-now-7593854","podcast_index_feed_id":7593854,"rss_url":"https://feeds.fastcast.ai/the-plano-daily-news-now.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/podcasts/the-plano-daily-news-now.jpg","author":"The Daily News Now!","episode_count":2015,"summary":"Hosted by Corey with the Story, Toronto News Today delivers daily coverage of everything happening in Toronto with fast, focused updates on local news, government, business, public safety, weather, and the stories shaping the city. From downtown developments to regional updates, the show keeps you informed on what matters most across Toronto. Each short episode highlights what matters most—including key updates, local trends, and stories shaping the city—produced by AI for speed, consistency, and clarity. Part of The Daily News Now network, Toronto News Today is built for listeners who want reliable local news coverage in a quick, easy-to-digest format. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-07-25T14:21:18.616941+00:00","page_url":"https://stenobird.com/podcast/toronto-news-today-2-min-news-the-daily-news-now-7593854"},"episode":{"title":"Daraxonrasib Doubles Pancreatic Cancer Survival","slug":"daraxonrasib-doubles-pancreatic-cancer-survival","published_at":"2026-06-01T19:49:12+00:00","page_url":"https://stenobird.com/podcast/toronto-news-today-2-min-news-the-daily-news-now-7593854/daraxonrasib-doubles-pancreatic-cancer-survival","show_page_url":"https://stenobird.com/podcast/toronto-news-today-2-min-news-the-daily-news-now-7593854","url":"https://api.fastcast.ai/audio/03db38b1-ac60-4446-91c2-2df19ee69b53.mp3","audio_url":"https://api.fastcast.ai/audio/03db38b1-ac60-4446-91c2-2df19ee69b53.mp3","summary":"A breakthrough drug called daraxonrasib is turning heads in pancreatic cancer treatment, doubling survival time for patients who didn’t respond to chemo. In a major trial, it stopped or reversed tumor growth in nearly a third of patients—far outperforming standard chemo—and pushed median survival from under seven months to around thirteen. Targeting the notorious KRAS mutation, it’s seen as a “game changer” by doctors, offering hope with fewer side effects. Though not yet universally approved, this first-of-its-kind therapy could unlock new treatments for other cancers driven by similar mutations. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/c7b234067ac39e4d","meta_description":"A breakthrough drug called daraxonrasib is turning heads in pancreatic cancer treatment, doubling survival time for patients who didn’t respond to chemo.…","key_points":[],"chapters":[],"topics":[],"duration_seconds":111,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/toronto-news-today-2-min-news-the-daily-news-now-7593854/episodes/daraxonrasib-doubles-pancreatic-cancer-survival/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/toronto-news-today-2-min-news-the-daily-news-now-7593854/daraxonrasib-doubles-pancreatic-cancer-survival.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}